MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
IOM Report on Genomics
Dear Cancer Center Members:
Please take the time to review an important new analysis from the Institute of Medicine, Genome-based Diagnostics: Demonstrating Clinical Utility in Oncology. The document provides expert opinions on development and use of biomarkers for detection, diagnosis, prognosis, and drug response in oncology; this includes genomic biomarkers. Although it does not specifically address genomic mutations as predictors of treatment and response, that is the direction it is headed. Given the importance of IOM reports in setting national standards, please consider and reference this document in your research and grant submissions. Also, a good bit of the orientation is towards validation through clinical trials and the development of approved companion diagnostics.
Stan Gerson, MD
Director, Case Comprehensive Cancer Center
CASE CCC IN THE NEWS
University Hospitals Performs Rare Procedure During Brain Bypass; Patient Goes Home for Holidays
The Plain Dealer - Nov 28, 2013
On Monday, Eric Wagner finally got surgical staples, lining a 6.25 inch curved scar, removed from the left side of his skull. He had gotten them 10 days earlier, during a 12-hour operation at University Hospitals Case Medical Center...Brain scans showed that Wagner had a ruptured aneurysm, a leaking blister on a blood vessel that was letting blood flow into his brain. Neuroradiologist Dr. Jeffrey Sunshine, UH's vice chairman of radiology, closed off the blister with a series of small titanium coils that stemmed the blood flow to that weakened area.
Debating the FDA Decision to Suspend Marketing and Sales of the Leukemia Drug Ponatinib (Iclusig)
Oncology Times - Nov 26, 2013
Early data reported late last year from the Phase II trials for the BCR-ABL tyrosine kinase inhibitor ponatinib (Iclusig) fielded much attention –so much, that the drug was approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) under the FDA's priority review program, which expedites the review process of promising new drugs. The latest findings give sufficient reason to pause and review the drug's safety, said OTs Clinical Advisory Editor for Hematology/Oncology, Mikkael Sekeres, MD, MS, Director of the Cleveland Clinic Taussig Cancer Institute's Leukemia Program and Chair of the Hematology/Oncology Pharmacy and Therapeutics Committee, and member of the Case Comprehensive Cancer Center.
Cleveland-based Akrotome Imaging's Technology Designed to Help Surgeons Find, Remove Cancer
The Plain Dealer - Nov 25, 2013
Women who have undergone a lumpectomy to remove a cancerous tumor from their breast – and the surgeons who treat them – don't know for several days if the tumor has been completely removed. Jim Basilion, a professor in the departments of radiology, biomedical engineering and pathology at CWRU and co-director of the Cancer Imaging Program for the Case Comprehensive Cancer Center, and his two partners at Akrotome Imaging Inc. hope that their patented guided imaging technology will one day eliminate the need for repeat lumpectomies (something that between 20 and 60 percent of women must endure) and also will save money in the process.
Borderline and Atypical ALK-Negative NSCLC May Benefit From Crizotinib; Researchers Say the Criteria Used Should Be Expanded, but Other Experts Say the Clinical Implications Remain Unproven
Oncology Times - Nov 25, 2013
The criteria used to identify patients with non-small-cell lung cancers (NSCLCs) who can benefit from treatment with crizotinib may omit an estimated 8.5 percent of patients who could benefit from the drug, according to research published in the November 15 issue of Cancer...Still, Nathan Pennell, MD, PhD, of the Department of Solid Tumor Oncology at Cleveland Clinic and the Case Comprehensive Cancer Center, said, it remains to be seen how relevant the findings are in actual clinical practice.
Genomic Test Helps Men with Prostate Cancer Choose Proper Treatment Path
Freshwater - Nov 21, 2013
Eric Klein, chair of the Glickman Urology and Kidney Institute at the Cleveland Clinic, along with a team of researchers at the Clinic and Genomic Health, have developed a genomic test that determines the aggressiveness of prostate cancer and therefore helps doctors and patients decide the proper course of treatment.
Drs. Richard Padgett and Edward Plow Honored by AAAS
Richard A. Padgett, PhD and Edward F. Plow, PhD were recently named as Fellows of the American Association for the Advancement of Science (AAAS) for their contributions to science. Dr. Padgett was recognized for his work with RNA processing, particularly in the areas of RNA splicing, the diversity of splicing mechanisms, and connections with disease. Dr. Plow was honored for his work with vascular biology, particularly for elucidating mechanisms of platelets, integrins, and plasminogen, and outstanding services to the cardiovascular community.
Ohio Cancer Research Associates Honors Dr. Stan Gerson for Contributions to Cancer Research
Ohio Cancer Research Associates, OCRA, an organization dedicated to the cure and prevention of the many forms of cancer, honored Case Comprehensive Cancer Center Director Dr. Stanton L. Gerson for his contributions to cancer research at the OCRA's Singular Sensation ceremony and banquet on November 22. Dr. Gerson was recognized for his substantial impact on patients and their families, his strong community advocacy, and for his work in cancer research.
Case CCC ACS IRG Pilot Award Recipients
Congratulations to the recent recipients of the Case CCC ACS IRG pilot awards:
- HyeonJoo Cheon, PhD: P53-dependent Regulation of STAT 1 Expression and Consequences for Cancer Therapy
- Frederic Reu, MD: Preclinical Studies on a New Anti-Myeloma Drug Candidate
- Basem M. William, MD: Modulation of graft versus leukemia (GVL) and graft versus host (GVH) responses by oral azacytidine hypomethylating therapy after allogeneic stem cell transplantation (SCT); An ancillary correlative science study
- Rong Xu, PhD: Network-based approaches in discovering novel off-targets underlying cardiotoxic effects caused by targeted cancer drugs
These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have national grant support of their own.
ASH Annual Meeting - Case CCC Participants
The American Society of Hematology Annual Meeting will be held December 7-10 in New Orleans. The Case CCC is pleased to have many members participating, presenting, and leading sessions. Please support your colleagues if you are attending the meeting. Congratulations to everyone!
AACI Translational Cancer Research Fellowship
The Case Comprehensive Cancer Center may nominate ONE candidate for the AACI Translational Cancer Research Fellowship. The intent of the fellowship is to provide additional support to individuals who are engaged in any area of clinical and/or translational cancer research in order to further the development of their careers and enhance their future success in an academic discipline. The AACI fellowship will provide a one-year non-renewable grant to support post-doctoral training to individuals who have completed at least one year of training in any field of oncology and have at least one year of training remaining at an AACI member institution. Interested candidates should forward a letter of support from their mentor and their 4-page NIH biosketch to Terri Daso at firstname.lastname@example.org by Friday, December 13.
Internal Deadline: December 13
External Deadline: February 3, 2014
Reissue of Genomics RFA
After internal discussion and a number of questions raised about the RFA: Pilot Grants: Use of Tumor Genomic Evaluation for Clinical Decision-Making, the Cancer Center reissued a revised RFA. We apologize to those investigators who worked feverishly to apply for the original deadline of December 2. However, we may not have been clear in our description of the overall intention and orientation of the work we would like to promote. The revised proposal makes clear that we would like to encourage human tumor high-throughput sequencing, including RNAseq, that is designed to inform future clinical studies in prognosis, treatment or treatment futility.
Revised Deadline: January 7, 2014
Society of Surgical Oncology
The Society of Surgical Oncology is accepting applications for the Clinical Investigator Award. The purpose of the award is to promote patient-oriented research conducted by surgical oncologists in clinical and translational science. Applicants must be surgical oncologists within 10 years of completion of training, and full SSO members for at least 6 months prior to application submission to be eligible for the award.
Deadline: January 13, 2014
MARK YOUR CALENDARS
Free Health and Wellness Webinar
On Wednesday, December 4 at 12 pm Dr. Smitha Krishnamurthi will present an online webinar discussing results of research on cancers of the pancreas, colon and rectum. She will review how the results of research have affected how medical professionals choose treatments; the way health decisions are made; and the health of the community. This educational event will end with opportunities for the attendees and community to ask questions and give suggestions for research ideas that are important to their community. The presentation will last 20 minutes followed by a brief Q&A session. Register by calling 216.285.4069.
Ohio Practice-Based Research Festival 2.0: The growing intersection of primary care and public health
Practice-based research networks are organizations of community practices that collaborate with academic and community partners to facilitate scientific discovery. For nearly two decades, hundreds of Northeast Ohio healthcare providers have conducted ground-breaking research through participation in practice-based research networks.
Clinicians, investigators, practice staff, and volunteers from primary care, public health and community settings are invited to attend a one-day festival, Ohio Practice-Based Research Festival 2.0: The growing intersection of primary care and public health, this Saturday, December 7 from 8 am - 3 pm at the Embassy Suites, Cleveland - Rockside. This festival will focus on the growing intersection of primary care and public health. This is an opportunity to share your ideas, disseminate your research findings, get input from others, learn about funding opportunities, develop your ideas, and build collaborations for future research endeavors. There is no cost to attend the festival, but registration is required.
Retreat: Engaging in Cultural Competence through Awareness, Knowledge and Action
Please mark your calendars for Thursday, March 13, 2014from 2-5 pm to join the Case Comprehensive Cancer Center and the Case Center for Reducing Health Disparities as they explore issues related to cultural competence. Extend your knowledge and raise your awareness about the dynamic variety of people and communities the Case CCC serves. This retreat will feature a keynote address by Dr. Sonja Harris-Haywood, and will provide perspective on the growing need to be culturally competent and facilitate the impact of cultural beliefs within the health care setting, specifically in research.
Pre-registration will be required due to limited space in the Wolstein Research Building Auditorium. Additional information will be posted soon. Please direct any questions to Katarzyna Karelus at 216.844.4176 or email@example.com.